On May 15, 2020, Changjiang Health Hailing Pharmaceutical and Chang’ao Group Liancheng Pharmaceutical successfully signed a contract on the cooperation of Lulite (Luliconazole Cream), and the two sides reached strategic cooperation on the product in the terminal retail markets such as primary hospitals, pharmacies and clinics. Upper managements such as Lu Yifeng, President of Changjiang Health and CEO of Hailing Pharmaceutical; Li Yiqing, Vice President of Changjiang Health; Xu Yan, General Manager of Chang’ao Group, and Fukui Mahito, Deputy General Manager of Changao Group attended the signing ceremony.
Lulite (Luliconazole Cream), which is a new generation of topical antifungal drug product, was innovated in Japan in 2005. Hailing Pharmaceutical has its exclusive compound patent and uses imported drug substances for production. It is indicated for the treatment of fungal infection of superficial skin caused by susceptibleorganisms, including tinea pedis, tinea corporis, and tinea cruris; as well as the treatment of cutaneous candidiasis and tinea versicolor. It can penetrate the skin quickly and has a broad antibacterial spectrum and powerful antimicrobial effect that lasts for 24 hours. In addition, its advantages such as high symptom improvement rate, not easy to relapse, short course of treatment, minimal side effects and less administration times are recognized by doctors and patients.
English
简体中文
